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Abstract. Background: A new approach to cancer therapy based 
011 the application of therapeutic electromagnetic fields (TEMF) 
has been developed by EMF Therapeutics, Inc., Chattanooga, 
TN, USA. This study was designed to assess the effect of TEMF 
011 tumor vascularization and growth of murine 16/C mammmy 
adenocarcinoma cells in C3H/HeJ mice. Materials and 
Methods: Implanted fllmors were allowed to grow for seven days 
until the tumor volume reached 100 mm3 before treatment was 
started. Mice (20 per control, 10 per £1\tJF erposed group) 
received treatment (10 minutes per day with 0, 10 mT, 15 mT or 
20 mT) with a 120 pulses per second pulsating magnetic field. 
Tumor giVwlh was assessed throughout the treatment period. 
The ertent of llmwr vascularization was evaluated by 
immrmohistochemical staining for CD31. Results: Erposure to 
TEMF significantly reduced tumor growth, significantly reduced 
tire percentage of area stained for CD31 indicating a reduction in 
the ertent of vascularization and there was a concomitant 
increase in the extent of tumor necrosis. Conclusion: A novel 
TEMF treatment safely reduced growth and vasculadzalion of 
implanted breast cancers in mice. Implication: TEMF may prove 
a useful adjuvant to increase the therapeutic index of con-
ventional cancer therapy. 
Angiogenesis is defined as the process of formation and 
development of new blood vessels from existing blood vessels. 
Angiogenesis occurs as a tightly regulated physiological 
process during periods of tissue growth, such as embryonic 
development, any increase in muscle or fat , during the 
menstrual cycle and pregnancy, as welt as in wound heating. 
However, neovascularization can contribute to a number of 
pathological processes such as rheumatoid arthritis, diabetic 
retinopathy, macular degeneration and tumor growth (1-4). It 
is safe to ~ay that angiogenesis is an important factor in the 
maintenance and progression of a number of disease states 
(1,3-6). A11giogel)esis may occur either as a natural response 
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to the underlying dise~se or as a contributory factor to disease 
progression. 
Alltiangiogenic therapy is a relatively new approach to the 
treatment of solid tumors. Since tumor angiogenesis is a 
fundamental step in tumor growth (7), any method that 
inhibits the formation and development of a blood vessel 
network in tumor tissue may lead to the reduction or 
cessation of tumor growth. No studies were found in the 
availl!ble literature on the use of magnetic fields to reduce 
angiogenesis. This study was designed to investigate the 
potential of pulsating electromagnetic fields to inhibit 
angiogenesis in an animal tumor model, specifically the 
murine 16/C mammary adenocarcinoma implanted into the 
C3H/HeJ mouse. 
Materials and Methods 
Animals Animal care and handling were performed at the Southern 
Research Institute (Birmingham, AL, USA). Fifty female C3HJHeJ 
mice, approximately six-weeks-old, were obtained from the Frederick 
Cancer Research and Development Center of the National Cancer 
Institute (Frederick, MD, USA). The mice were housed in plastic 
microisolator cages with sterile hardwood bedding ·and had free access to 
a standaro laboratory diet and fi ltered tap water. They were weighed on 
the day of tumor implantation, on days 8, 10, 14 and 17 after tumor 
implantation and at sacrifice. Air temperature and relative humidity in 
the animal rooms were controlled at (24±1)"C and (50±10)%, 
respectively. The lights were operated on automatic 12-hour light/dark 
cycles. The ambient magnetic fi eld in the exposure chamber was below 
50jtT. 
Implantation of tumors. The murine 16/C mammary adenocarcinoma 
cells (National Cancer Institute collection) were first implanted 
subcutaneously in C3H/HeJ mice and the resulting tumor was 
maintained by routine passages in vim in mice prior to implantation (8). 
The tumors were implanted ria a singiG subwtaneou; inje~tion in th~ 
medial left torso (9) of 30 mg of tumor fragments derived from a 
primitive tumor (10). All implanted tumor fragments were obtained 
from passage 5 of the adenocarcinoma cell line. The animals were 
randomized between control (20 animals) and three treatment groups 
(10 animals per group) after the tumors reached palpable size. 
\ 
Magnetic fieltl device. A therapeutic electromagnetic field (TEMF) 
system having a proprietary signal designed by ElviF Therapeutics, Inc. 
(Chattanooga, TN, USA) was used. The system generates a pulsating 
half sinewave magnetic field with a frequency of 120 pulses per second 
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Figure I. Representation of the f ully rectified 60Hz signal iransfe,red to 120 
pulses per second pulsating magnetic field. 17Je amplitude of the field 
depends on the cwrelll supplying the coil, b1~t the wm·efonn remains the 
same. 
· ' 
(Figure l). An ellipsoidal coil with 21" large diameter and 14" small 
diameter is used to deliver the signal to the target. In the experiment 
reported here, the magnetic filL~ density measured in the exposure 
chamber was 10 mT, 15 mT or 20 mT. These values of. magnetic field 
flux density were chosen to investigate the dose-response dependence 
based ·upon our previous experience and data (11): A thorough 3-D 
mapping of the magnetic field was performed for the entire space 
covered by the coil. The flux density o f the magnetic field in the 
, ' 
I) 
exposure chamber (25 em long; 10 em wide and 13 em high) was 
consistent within the entire volume ·of the chamber. TI1e walls of the 
exposure chamber were perforated to allow air exchange between the 
,- : exposure chamber and environment. The temperature change inside the 
exposure chamber at the end of the TEMF treatment did no t exceed t • 
C, and this change was probably a result of body heat emitted by the 
mice. 
Treatment with magnetic field. The treatment of the animals started after 
the tumor volume reached approximately 100 mm3 (evaluated by cal iper 
·and calculated by the standard formula discussed below) at day 7 after 
the tumor \Vas implanted. The animals received magnetic field treatment 
for 10 minutes daily over I 2 consecutive days. 1l1e duration of the daily 
sessions was selected based upon our previous study (ll). The control 
group mice remained in their housing except during the measurement o f 
tumor volume and body weight. 
Tumor. growth. The tumor volume was calculated by the standard 
procedure using the fo rmula V= (AB2)/2 where A is the longer diameter, 
a nd n is the smaller d iameter of the tumor. The same fo rmula for tumor 
volume was used in a recent publication (12). 1l1e length and width of 
each tumor was measured \\~th calipers o n days 8, 10, 14, 17 and 20 after 
implantation. 
lmmrmohistochemistry. The effect of TEMF on angiogenesis was 
evaluated by the expression of CD3l. CD31 (platelet endothelial cell 
adhesion molecule, PECAM-1) is a 130 kDa integral membrane protein . 
that mediates cell-to-eel! adhesion and is expressed at the surface of 
endothelial cells. Cross sections of the tumors were cut perpendicular to 
the underlying muscle layer. The tumor. sections for CD3! immuno· 
histochemistry were prepared and stained fo r CD3l at the Southern 
Research Institute, (Birmingham, AL, USA). (13). The 12-15 Jim-thick, 
frozen sections were placed on negatively charged ChemMate slides 
(Venta nt, Tucson, AZ, USA), air dried 'for 24 hours a nd fLxed in 
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Figure 2. Volum·e· (Mean ± SEM 1111n3} of murine 16/C breast 
adenocarci1wma in control group and in groups of mice exposed to 10, 15 
or 20 mT TEMF for 10 minutes per day for 10 days. Trmwry ll'ere measured 
prior to the first exposure {day 8) and 011 days 10, 14 and 17. ANOVA 
fol/OII'ed by SNK of the group mean volumes re~•eQ/ed that by day 17 the 
tumory of the <;antral group 1\'e;e significamly larger than the tumors of all 
three of the EMF-treated groups. I11e differences bel!l'een the tumor 
mlumes of the three EMF-treated groups were not statistically significant. 
Table I. Tumor growth during treatment period - day 8 through day 17. 
Tumor growth is shown as the increase in trmwr volume (1•olume at day 17 
minus volume at day 8). 
Treatment Group Tumor Gro\\1h SEM 
(mm3) (mm3) 
Control 3567 239 
lOmT 2945 186 
15mT 2807 169 
20 mT 2563 252 
acetone. Immunohistochemical staining was performed using a 
Techmate Automated Stain ing System and rat anti-mouse CD 31 
(Pharmingen, San Diego, USA) monoclonal antibody. Rat TgG2a 
isotypic serum was used as a negative contro l. Binding was visualized 
using biotinylatcd rabbit anti-rat immunoglobulin followed by 
streptavidin·horseradish peroxidase and diaminobenzidine. 
Morphometric analyses for the percent of CD31 in viable and in 
necrotic areas were performed on a subset of tumo rs randomly sampled 
from the control group and each treatment group. The cryosectioned 
tumors previously stained for CD31 reactivity were analyzed using phase 
contrast microscopy to differentiate necrotic, \oiable a11d CD31-stained 
regions of each tumor. Glid intercept point counting was used to 
estimate the fraction of an area covered by necrotic, viable or CD3 l· 
positive areas. 
Statistical analyses. Differences between gro ups in mean tumor size at 
each time point and body weights were evaluated by analyses of variance 
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Figure 3. Effect of exposure for 10 minutes per day for /0 days to a 10, 15 
or 20 mT TEMF on tlze percent of 111mor area imml/nohistochemically . 
positirefor CD31. 17ze mean CD31-positil'e area of eaclztwnor is shown in 
the Jcattergram. Groups with different lettet~ ar-e significantly different. 
AN OVA followed by SN K statistics rerealed the tumors of the control group 
to hm·e a sig11ijicantly greater area of CD3 J-positi1 ·e mswlar tissue than the 
three EMF-treated groups am/ the tumon of the 10 mT-exposed group to 
hare a significantly greater area of mscu/ar tissue than the groups exposed 
to 15 mTor 20 mT. 
(ANOVA) fo llowed by a Student-Newman-Kuels (SNK) multiple range 
test. Fisher's Exact test was used to compare mortality proportions of the 
groups. Linear regression analysis was used to compare the relationship 
of the vascular (CD31-positive) area to the necrotic fraction in the 
tumors. 
Results 
Body mass and mortality. There was no significant difference 
in the increase in body mass of the treatment groups as 
compared to the control group. Thus, TEMF exposure did 
not affect the body mass of the mice. All mice in all groups 
were alive on the 17th day after !umor implantation. By 20 
days after implantation, 40% (8 out of 20) of mice in the 
control group, 40% ( 4 out of 10) of mice in the 10 mT group, 
30% (3 out of 10) of mice in the 15 mT group, but only 10% 
(1 out of 10) of mice in the 20 mT group had died. Although 
there was less mortality in the 15 mT and 20 mT groups, the 
differences were not significantly different by Fisher's Exact 
test. Thus, as judged by body weight and mortality, the EMF 
treatment did not result in detrimental effects to the mice. 
Tumor growth. Figure 2 is a graph of the mean tumor size of 
each group for the first 10 days of treatment (days 8 through 
17). Days 18 to 20 were not included because of the mortality 
observed between days 17 and 20. The tumor growth curves 
begin to diverge as early as two days after the first TEMF 
treatment. Following 10 days of TEMF treatment, the control 
group mice had significantly larger tumors than the TEMF-
treated mice. The effect on tumor growth is also seen by 
comparing the gaiu in tumor volume during the TEMF 
treatment (volume at day 17 minus volume at day 8 (the day 
treatment_ began)).· Table I shows that tumor growth during 
Figure 4. The photomicrograph is of 12 to /5JmHhick sections of a 16/C 
murine mammmy adenocarcinoma. 17ze 111mor section was subjected to 
immwwhistoclzemistty to detect the preseizce of CDJ I, a marker for blood 
1·essels. Blood ••essels (arrowheads) are visualized by the presence of the 
dark stain for CD 3/. Areas of viable tissue are seen adjacent to the blood 
\"essels. Necrotic areas (N) are located fimher from the blood \'essels and 
contain condei!Sed nuclei and cell fragments. 
TEMF treatment was significantly less in the treatment 
groups than in the control group. The greatest reduction 
from control was found in the 20 mT-treated group (p < 
0.01). There was no statistically significant difference among 
the TEMF-treated groups (p < 0.45). 
Immrmohistochemist1y. Figure 3 shows the effect of TEMF 
exposure on the percent of tumor area stained positive for 
CD 31. All amplitudes of TEMF significantly reduced the 
percentage of CD31 staining. The percentage of CD31 
staining decreased from (7.56±3.35)% in the control group to 
( 4.60±2.20)% in the 10 mT group, (2.42± 1.13)% in the 15 
mT group and to (2.86± 1.06)% in the 20 mT group. AN OVA 
indicated that CD31 staining was significantly less in all 
treated groups than in the control group (p<O.OOI). The 
CD31 staining in the group exposed to 10 mT was 
significantly less (p<O.OOl) than in the groups exposed to 15 
mT or to 20 mT. The difference in CD31 staining between 
the group exposed to 15 mT and the group exposed to 20 mT 
was not statistically significant (p<0.1). 
The change of mean percent of CD31 staining in th~ 
TEMP-treated groups vs. mean percent in the control group 
was used to demonstrate the effect of TEMF treatment on 
angiogenesis iu the tumor. CD31 staining in the tumor was 
sign ificantly decreased 39% by 10 mT TEMF treatment, 68 % 
by 15 mT TEMF treatment and 62% by 20 mT TEMF 
compared to staining in the tumors of the control group. 
The use of CD31 as a specific marker for blood vessels was 
confirmed by comparison of bright field with phase contrast 
microscopy. Phase contrast microscopy of the tumor tissue 
revealed that viable, necrotic and CD 31-positive areas could 
be differentiated as seen in Figure 4. Figure 5 illustrates the 
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significant inverse correlation between vascular area (CD31-
positive) and the necrotic area in the tumors. These figures 
show that the TEMF treatments significantly decreased the 
vascular density of the tumor and increased the volume 
density of necrotic tissue in the tumors. 
Discussion 
Quantifying the CD31 staining was based on the 
densitometric analysis of the percentages of immunostained 
areas related to total area of interest (14,15). In normal 
tissues a strong and homogeneous expression of PECAM-1 
can be observed exclusively in endothelial cells of capillaries 
and in large vessels (16). Therefore, the diminished 
percentage of CD31 staining demonstrated in Figure 3 should 
be interpreted as a reduction in vascularity in the tumor. 
The results reveal that: 
+ TEMFs significantly inhibited both angiogenesis and tumor 
growth; 
+ The largest inhibition of angiogenesis was observed in the 
group exposed to 15mT TEMF and the largest inhibition 
of tumor growth was observed in the group exposed to 
20mTTEMF; 
+ The differences between inhibition of angiogenesis and 
tumor growth in the 15mT and 20mT groups were not 
statistically different, thus this study supports the 
hypothesis that a biological window of efficacy exists within 
the range of 15-20 mT magnetic field amplitude. 
It appears that the inhibition of angiogenesis leads to a 
reduction in tumor growth. One possible reason for this may 
be found in the suppressed development of the blood-vessel 
network which in turn leads to a deficit<ncy in supplying tumor 
cells with oxygen, ions and nutrie11ts. Cells must be located 
within about 150 ~1m of a blood vessel for diffusion to 
adequately meet the ox-ygen and nutrient requirements for 
cell viability (17), thus growth and viability of the tumor 
strongly depends on angiogenesis. The observed increase in 
necrotic tissue and decrease in CD31-positive area supports 
the need for vascularization to maintain tissue viability. 
The use of CD31 as a specific marker for blood vessels was 
confirmed by comparison of bright field with phase contrast 
microscopy. Observation of the tumor sections by phase 
contrast microscopy revealed that viable tumor cells were 
found adjacent to the blood vessels, while areas of tumor at 
distances greater than 75-150 ~1m from any blood vessel were 
necrotic. 
The grid intercept method data establishes a relationship 
between the fraction of CD31-positive area and the necrotic 
fraction. The results were graphed and analyzed for non-
linear regression analysis. A statistically significant (p<0.001) 
negative relationship between the fraction of necrotic tissue 
and the fraction of vascular tissue was found, that is, the area 
of necrosis decreased logarithmically as .the vascular area 
increased. This negative relationship was confi rmed by the 
analyses of variance that revealed a significant difference 
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between the necrotic volume in the control samples and 
samples from animals exposed to TEMF. 
The results suggest that therapeutic effects may be 
achieved by an appropriate selection of the physical 
parameters of the applied magnetic fie lds. It has been shown 
that it is more appropria,te to consider biological response to 
magnetic fields through the hypothesis of "biological 
windows" instead of dose-response dependence. The bio-
logical response probably depends not only on the amplitude 
of the applied magnetic field but on some other physical 
characteristics, such as waveform, frequency, repetition rate, 
presence/absence of the electric field component, etc. (18). 
The results shown in this study confirm reports of an 
amplitude window in the range of 15-20 mT (19). 
At present, we have not hypothesized a mechanism to 
explain the antiangiogenic effect of the TEMF in this tumor 
model; however, there are a number of candidate targets for 
magnetic field action. As tumor cells proliferate into the host 
tissue, tumor angiogenesis leads to the formation of a new 
tumor vasculature. Tumor microcirculation originates from 
the normal host vasculature, but the tumor vessels are more 
dilated, sacular and tortuous. Furthermore, tumor vasculature 
has wider intercellular junctions. The extravasion of blood-
borne molecules that have reached the tumor vasculature is 
governed by .diffusion and convection (17). TEMF may 
modify the ability of those molecules to move within the 
tumor tissue. 
The results presented in this paper allow us to conclude 
that a pulsating magnetic field (120 pps) may inhibit the 
formation of a blood-vessel network in a growing tumor and 
that the suppression of the blood-vessel network is probably 
the main cause of necrotization of the tumor interior and the 
reduction of tumor growth rate. Whether this effect is 
repe~table and valid for all types of tumors and whether the 
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treatment regimen applied to experimental animals will be 
effective in human tumors remains to be seen. Several studies 
are ongoing using different protocols to explore these issues. 
Although the data from this study reveal that TEMF therapy 
suppressed vascularization of the tumor and slowed tumor 
growth, the TEMF-treated tumors did not regress. Is there a 
rationale for continuation of TEMF therapy research given that 
the tumors did not regress? Folkman et al. (20) make the point 
that tumors consist of.cancer cells whose genome is often too 
unstable to seiVe as a ftxed therapeutic target and that the 
cancer cell can acquire dntg resistance through natural selection 
of viable genetic variants within the cancer cell population. The 
cancer cells in the tumor are known to overexpress factors that 
stimulate gene expression and the proliferation of endothelial 
cells thus allowing continued expansion of the tumor. Even 
though the tumor endothelial cells have up-regulated expression 
of at least 79 genes compared with "resting" endothelial cells 
elsewhere in the body, the non-transformed vascular endothelial 
cells of the tumors have a relatively stable genome. Thus, the 
tumor endothelial cells are a less variable therapeutic target 
than are the genomically unstable cancer cells. The cancer cell 
mass simply can not evade the need for angiogenesis if it is to 
grow (20). The targeting of tumor endothelium versus tumor 
cancer cells should not be considered as mutually exclusive 
therapies but anti-angiogenic therapy can, with benefit, be 
combined with therapies directed towards the cancer cell. Such 
cancer cell-directed methods include radiation, chemical, 
immuno- and gene therapies. At present there are multiple 
reports and ongoing studies on the use of anti-angiogenic 
chemotherapy for treatment of cancerous tumors (20). The 
findings from the TEMF study reported herein odd TEMF as a 
simple, safe and non-invasive physical anti-angiogenic tumor 
therapy that warrants further investigation in combination with 
currently used cancer cell-directed therapies. Such a 
combination approach may have additive or synergistic 
therapeutic value for treating tumors. 
Several studies have indicated a synergistic effect between 
magnetic fields and commonly used chemotherapeutic agents 
(21 - 24). We are pursuing further studies using different 
tumor models and exposure conditions to explore the 
combined action of TEMF and cytostatic agents and to 
investigate whether the hypothesis of biological windows is 
applicable to the obseiVed anti-angiogenic and tumor growth 
effects ofTEMF. 
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